News
Sobi pays $1.5bn for Arthrosi to grow in gout
Sobi has hit the acquisition trail with a deal to buy Arthrosi Therapeutics for up to $1.5 billion, adding a drug in late-stage testing for gout.
Sunday 1 February 2026
